Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indications The import was conducted in collaboration with the government of Peru Steven King, Ph.D. of Jaguar to speak about the potential promise of coca-based Botanical Drugs at the February 2025 Wisdom of the Leaf Coca Summit in Peru Magdalena is focused on developing novel, natural prescription medicines...Read more
The study is one of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of MVID and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of first IIT proof-of-concept results potentially in Q1 2025 Crofelemer, Jaguar's novel plant-based prescription drug, has...Read more
LANSING, Mich., Dec. 17, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, has introduced a new addition to its Petrifilm® product line, the Neogen Petrifilm Bacillus cereus Count Plate. This innovative new solution offers food safety professionals a simple, reliable, and efficient method for testing for Bacillus cereus, a persistent threat with potentially deadly consequences. The...Read more
Crofelemer is the subject of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - for the rare disease indications of microvillus inclusion disease (MVID) and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of IIT proof-of-concept results potentially in Q2 2025 Virtual event 11:00 AM to 12:00 PM...Read more
Adult patients with breast cancer are a prespecified subgroup of the recently conducted phase 3 OnTarget trial evaluating crofelemer for prophylaxis of CTD The majority of patients in the OnTarget placebo group on abemaciclib and pertuzumab-based therapies required dose reduction or elimination SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals...Read more
TORONTO and PHILADELPHIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce that its Investigational New Animal Drug (INAD File No.013880) has received Minor Use in Major Species Designation (“MUMS”) from the U.S. Food and Drug Administration (“FDA”) for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell...Read more
ANN ARBOR, MI / ACCESSWIRE / November 27, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that its Chief Executive Officer, Larry Heaton, will present and host one-on-one meetings with investors at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity...Read more
GREENFIELD, Ind., Nov. 15, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today acquired a contract manufacturing facility and related assets in Speke, UK. The facility, previously owned by TriRx Speke Ltd., was under trading administration, a formal insolvency process in the United Kingdom. As previously shared on the Company's third quarter 2024 earnings call, the Speke facility plays a vital role for...Read more
Combined with Zomedica's eACTH assay, equine veterinarians get same day answers for their PPID and EMS patients ANN ARBOR, MI / ACCESSWIRE / November 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of its third equine-focused assay - Insulin for equine plasma...Read more
PORTLAND, Maine, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2024. Q3 2024 Highlights: Product sales...Read more
The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 million Jaguar reported significant results in breast cancer patients in its phase 3 OnTarget trial for its cancer supportive care drug crofelemer; results in breast cancer patients...Read more
Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are...Read more
New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize Global Commercial Operations PARSIPPANY, N. J. / Nov 11, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world’s leading animal health company. In this new role, Mr....Read more
ANN ARBOR, MI / ACCESSWIRE / November 8, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Larry Heaton, Chief Executive Officer, will present and host one-on-one meetings with investors at the Sidoti Micro Cap Conference, taking place on November 13-14, 2024. The...Read more
ANN ARBOR, MI / ACCESSWIRE / November 7, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the third quarter ended September 30, 2024. "We are very pleased with our performance, highlighted by record third quarter revenue and a double-digit...Read more
Third Quarter 2024 Financial Results Revenue of $1,030 million, organic constant currency growth of 1% Reported Net Income of $364 million, Adjusted Net Income of $66 million Adjusted EBITDA of $163 million, or 15.8% of Revenue Reported EPS of $0.73, Adjusted EPS of $0.13 Net leverage ratio of 4.3x Adjusted EBITDA Pre-tax gain of $640 million from July 2024 divestiture of the aqua business Tightening full year 2024...Read more
TEANECK, N.J. / Nov 06, 2024 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2024, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended September 30, 2024 (compared to the three months ended September 30, 2023) Net sales of $260.4 million, an increase of $29.1...Read more
Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIRE / November 6, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX), under its Jaguar Animal Health...Read more
Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) A second late-breaking abstract related to the OnTarget trial, based on data from the placebo arm of the study, has also been accepted for a poster presentation at SABCS SAN FRANCISCO, CA / ACCESSWIRE / November 4, 2024 / Jaguar Health, Inc....Read more
Reports Revenue of $2.4 Billion, Growing 11%, and Net Income of $682 Million, or $1.50 per Diluted Share, Increasing 14% and 16%, Respectively, on a Reported Basis for Third Quarter 2024 Delivers 14% Operational Growth in Revenue and 15% Operational Growth in Adjusted Net Income for Third Quarter 2024 Reports Adjusted Net Income of $716 Million, or Adjusted Diluted EPS of $1.58, for Third Quarter 2024 Raises Full Year 2024 Revenue...Read more
Achieves third quarter revenue growth of 7% as reported and 6% organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic. Organic revenue growth supported by benefits from IDEXX execution drivers including continued solid new business gains and double-digit year-over-year global premium installed base growth. Delivers EPS of $2.80, an increase of 11% as reported and 12% on a comparable basis, supported...Read more
It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the abstracts are now available for two independent investigator-initiated studies of crofelemer, Napo's novel, plant-based oral prescription drug, that show a benefit in patients with chronic refractory...Read more
New Ear Cytology protocol significantly improves veterinary practice workflow by reducing total time to perform common diagnostic procedure ACCESSWIRE / October 24, 2024 / ANN ARBOR, MI / ACCESSWIRE / October 24, 2024/ Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the release of...Read more
Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M Ramat Gan, Israel, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that its veterinary partner Vetbiolix reported...Read more
Gelclair® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Severe mucositis/pharyngitis occurred in 70% of head and neck cancer patients in third-party study SAN FRANCISCO, CA / ACCESSWIRE / October...Read more
Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in 2025 SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX) today announced that Dr. Karen Brunke, Jaguar's EVP of Corporate and...Read more
Revenue of $217.0 million. Net loss of $12.6 million; $(0.06) per diluted share. Adjusted Net Income of $14.4 million; $0.07 per diluted share. Adjusted EBITDA of $43.7 million. Maintaining full-year guidance. LANSING, Mich., Oct. 10, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today the results of the first quarter ended August 31, 2024. "During the first quarter, the focus of our teams shifted from...Read more
SAN FRANCISCO, CA / ACCESSWIRE / October 8, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar") today announced that a late-breaking abstract evaluating the incidence, severity and management of diarrhea from targeted therapies with or without standard chemotherapy in the cohort of adult patients with breast cancer in the placebo group of the OnTarget phase 3 study recently conducted by Jaguar family company Napo Pharmaceuticals, was...Read more
Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first and only canine oral parasiticide to protect against six parasites, including fleas, ticks, heartworms, roundworms, hookwormsii and three different species of tapeworm that other brands skip creating a gap in coverageiii Warming temperatures and changing consumer habits have increased parasite pressure and spread across geographies,...Read more
Expansion adds new countries to Grovet's existing PulseVet distribution coverage and enables launch of the TRUFORMA® equine platform in Europe ANN ARBOR, MI / ACCESSWIRE / October 3, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the expansion of its distribution...Read more
Richland WA N, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. We recently treated our first exotic animal, a ferret, with encouraging results, seeing a considerable reduction in tumor size after three weeks. Treatment options for cancer in small exotic animals remain limited, and the current standard of care—surgical tumor removal—can be too invasive for exotic animals. Dr. Korenko commented, “While we have...Read more
PARSIPPANY, N.J. / Sep 26, 2024 / Business Wire / Zoetis and Danone recently announced a joint business development plan to drive sustainable practices on today’s dairy farms through the power of genetics for healthier cows. Combining Danone’s commitment to environmental stewardship with Zoetis’ expertise in animal genetics, the partnership aims to innovate the dairy industry’s approach to breeding for sustainability. The plan between the...Read more
Innovative technology represents a breakthrough scientific achievement for one of the most common feline infectious diseases RAHWAY, N.J. / Sep 24, 2024 / Business Wire / Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the expansion of the newly USDA-approved NOBIVAC® NXT vaccine platform to include a best in...Read more
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that its veterinary partner Vetbiolix exercised its option and...Read more
Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Up to 40% of all patients treated with chemotherapy develop oral mucositis, and this percentage rises to approximately 90% for patients with head and neck cancers treated with chemotherapy and radiotherapy SAN FRANCISCO, CA / ACCESSWIRE / September 24, 2024 / Jaguar...Read more
U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitis Elanco enters the estimated $1.7 billion global canine dermatology market, highly accretive to existing portfolio In a head-to-head study, Zenrelia was shown to be at least as effective as the market incumbent JAK inhibitor at the primary end point, with an additional endpoint at which Zenrelia got 77% of...Read more
SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on September 19, 2024 at the MedInvest Biotech & Pharma Investor Conference and participate in one-on-one meetings at the event, which is taking place September 18-19 in New York City. Participation Instructions for Jaguar Health's Presentation...Read more
FDA-approved Gelclair® is company's third commercialized prescription product Susan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Susan Krizancic to the role of National Sales Director for Jaguar family...Read more
SAN FRANCISCO, CA / ACCESSWIRE / September 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will be presenting virtually, and meeting virtually with investors, at the H.C. Wainwright 26th Annual Global Investment Conference, which takes place September 9-11, 2024. Participation Instructions for Jaguar Health's Presentation at the H.C. Wainwright 26th Annual Global...Read more
CE Mark approval opens European market for TRUVIEW system ANN ARBOR, MI / ACCESSWIRE / September 5, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced it has secured the CE Mark for its revolutionary TRUVIEW™ digital microscopy and telepathology platform. The CE Mark...Read more
Assisi's tPEMF™ technology aligns with Fear Free's mission to “prevent and alleviate fear, anxiety, and stress in pets” ANN ARBOR, MI / ACCESSWIRE / August 29, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering therapeutic and diagnostic products for equine and companion animals, is pleased to announce that its Assisi Loop® product line is continuing its designation as a Fear...Read more
TEANECK, N.J. / Aug 28, 2024 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2024 and provided its financial guidance for the year ending June 30, 2025. Highlights for the three months ended June 30, 2024 (compared to the three months ended June 30, 2023) Net sales of $273.2 million, an increase of $18.1...Read more
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the...Read more
Increased functionality makes the VETGuardian system a must have for veterinarians ANN ARBOR, MI / ACCESSWIRE / August 22, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company", a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, announced the introduction of advanced audio capabilities for its VETGuardian Zero-touch remote vital signs monitoring...Read more
WESTBROOK, Maine / Aug 21, 2024 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Jay Mazelsky, President and Chief Executive Officer, and Brian McKeon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 from 11:30 am – 12:05 pm...Read more
Leading veterinary experts to present at the Fetch dvm360 Veterinary Conference in Kansas City, August 23-25, 2024 ANN ARBOR, MI / ACCESSWIRE / August 20, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced its sponsorship of educational programs at the upcoming Fetch dvm360...Read more
Company's broad spectrum parasiticide on-track for October U.S. approval and first quarter 2025 launch GREENFIELD, Ind., Aug. 20, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has completed its review of all major and minor technical sections for Credelio Quattro, and the final 60-day administrative review is underway. "This is an exciting time at...Read more
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the...Read more
Study finds that the aggressive lone star tick is no match for Credelio GREENFIELD, Ind., Aug. 15, 2024 /PRNewswire/ -- Parasites & Vectors, a leading peer-reviewed journal focused on parasites and vector-borne pathogens published the results of a head-to-head study demonstrating that Credelio, a prescription flea and tick protection product from Elanco Animal Health, has the fastest initial speed of tick kill in just 12 hours...Read more
Diagnostic revenues up 68% year-over-year ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the second quarter ended June 30, 2024. "We are pleased with the progress in the quarter, which represents the...Read more
SIRE Veterinario, SA Selected as Distribution Partner to Launch Zomedica® Products into Costa Rica ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the latest expansion of its sales reach into Costa Rica. SIRE Veterinario, S.A. will be...Read more
PORTLAND, Maine, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2024. Q2 2024 Highlights: Product sales...Read more
The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus net Q2 2023 revenue of $2.67 million Company to complete analysis of full data for first and second 12-week periods of pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) in support of FDA...Read more
Raises Full Year Revenue and Maintains Adjusted EBITDA Guidance Excluding Aqua Divestiture Second Quarter 2024 Financial Results Revenue of $1,184 million Reported Net Loss of $50 million, Adjusted Net Income of $147 million Adjusted EBITDA of $275 million, or 23.2% of Revenue Reported EPS of $(0.10), Adjusted EPS of $0.30 Net leverage ratio of 5.6x Adjusted EBITDA Year over year growth rates are meaningfully impacted by a...Read more
EAGLE, Idaho, and NEW YORK, New York, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, health and wellness company, and Bansk Group (“Bansk”), a consumer-focused private investment firm dedicated to building distinctive consumer brands, today announced that PetIQ entered into a definitive agreement (the “Agreement”) pursuant to which Bansk Group will acquire all of the...Read more
Generates Record Second Quarter 2024 Net Sales and Net Income Record Adjusted EBITDA of $39.0 Million Exceeds Company's Second Quarter 2024 Guidance PetIQ and Bansk Group Sign Definitive Merger Agreement EAGLE, Idaho, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, product and wellness company, today reported financial results for the second quarter and six months...Read more
Reports Revenue of $2.4 Billion, Growing 8%, and Net Income of $624 Million, or $1.37 per Diluted Share, Decreasing 7% and 6%, Respectively, on a Reported Basis for Second Quarter 2024 Delivers 11% Operational Growth in Revenue and 18% Operational Growth in Adjusted Net Income for Second Quarter 2024 Reports Adjusted Net Income of $711 Million, or Adjusted Diluted EPS of $1.56, for Second Quarter 2024 Raises Full Year 2024 Revenue...Read more
Achieves second quarter revenue growth of 6% as reported and 7% organic, supported by CAG Diagnostics recurring revenue growth of 6% as reported and 7% organic. Solid growth supported by continued benefits from IDEXX execution drivers, including record second quarter premium instrument placements and double-digit year-over-year global premium instrument installed base growth. Delivers EPS of $2.44, a decline of 9% as reported...Read more
Dr. Elisabetsky is also an advisor to Magdalena Biosciences, the joint venture formed by Jaguar and Filament Health focused on identifying the next generation of plant-based first-in-class agents for treatment of mental health conditions As announced, Jaguar recently executed an out-license deal with Magdalena Biosciences for a botanical drug candidate for possible schizophrenia and psychoses indications and for development with...Read more
New patent issued for core rare disease target indication for crofelemer Jaguar has approximately 200 patents issued and pending Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome (SBS) and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, and Middle East/North Africa regions, with proof-of-concept results expected before...Read more
Revenue of $236.8 million. Net loss of $5.4 million; $(0.02) per diluted share. Adjusted Net Income of $22.4 million; $0.10 per diluted share. Adjusted EBITDA of $53.0 million. LANSING, Mich., July 30, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today the results of the fourth quarter ended May 31, 2024. "After crossing multiple significant integration milestones in the third quarter related to the...Read more
Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across all tumor types. Trial did reveal clinically relevant signals for crofelemer in prespecified subgroups of patients with breast and respiratory cancer, including lung cancer. Jaguar to host investor webcast Tuesday, July 23rd at 8:30 AM Eastern to provide updates on company's cancer supportive care...Read more
The clinical study of new potential VELDONA-based animal drug is poised to expand VELDONA's market. This clinical trial aims to complete the enrollment of 30 subjects by the end-2024 with the trial report to be finalized in Q1 2025. SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and...Read more
Webcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis; Click here to register for webcast Jaguar expands Make Cancer Less Shitty (MCLS) patient advocacy program to incorporate select group of MCLS Ambassadors -...Read more
New patents issued for core rare disease target indications for crofelemer Napo has approximately 200 patents issued and pending Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, and Middle East/North Africa regions, with results expected in 2024 and 2025 SAN FRANCISCO, CA / ACCESSWIRE...Read more
BLOOMFIELD HILLS, Mich. / Jul 08, 2024 / Business Wire / ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day confirmatory study targeting coccidiosis in collaboration with a major global animal health company. This new study aims to further validate the...Read more
PulseVet® Shock Wave Device Supports Equine Athletes Ahead of Major International Team Events ANN ARBOR, MI / ACCESSWIRE / July 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, is honored to announce that the United States Equestrian Federation (USEF), which regularly competes in FEI...Read more
Petrifilm end-to-end solution reduces hands-on enumeration time from 4 hours to 1 minute LANSING, Mich., June 27, 2024 /CNW/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, is helping high-volume food safety testing laboratories implement a more efficient way to process quality indicator tests. Today's launch of Neogen's Petrifilm® Automated Feeder will provide industry-leading indicator...Read more
First-of-its-kind stall-side testing to enable rapid, life-saving decisions for equine veterinarians ANN ARBOR, MI / ACCESSWIRE / June 27, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for equine and companion animals, today announced the commercial launch of its second equine focused assay - Cortisol for equine serum - for the...Read more
Major technical sections complete for Zenrelia, with FDA final approval on track for late in third quarter of 2024; updates on differentiation and safety Final FDA approval for Credelio Quattro now expected in the fourth quarter of 2024 First Zenrelia approval received in Brazil 2024 Innovation sales guidance increased GREENFIELD, Ind., June 27, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN)...Read more
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease RAHWAY, N.J. / Jun 25, 2024 / Business Wire / Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Department of Agriculture (USDA) approval of NOBIVAC® NXT Canine Flu H3N2, a next-level solution to...Read more
CE mark enables launch of the TRUFORMA® Diagnostic Platform into the European Union ANN ARBOR, MI / ACCESSWIRE / June 25, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced it has secured the CE mark for its proprietary point-of-care TRUFORMA Bulk Acoustic Wave (BAW)...Read more
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X anti-cancer vaccine is therapeutically effective against pre-established ovarian cancer (ID8 model) when combined with...Read more
ANN ARBOR, MI / ACCESSWIRE / June 10, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Peter Donato, EVP and Chief Financial Officer, will present and host one-on-one meetings with investors at the Sidoti Small Cap Conference, taking place on June 12-13, 2024. The...Read more
New research data confirms superiority of TRUFORMA's Bulk Acoustic Wave Sensor technology in diagnosing feline hyperthyroidism ANN ARBOR, MI / ACCESSWIRE / June 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the presentation of research highlighting the improved...Read more
The launch of the Catalyst® Pancreatic Lipase Test demonstrates IDEXX's Technology for Life strategy and will provide veterinarians with quantitative results at the point-of-care in less than 10 minutes WESTBROOK, Maine, June 4, 2024 /CNW/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the Catalyst® Pancreatic Lipase Test, a single-slide solution for canine...Read more
Improved precision and greater accuracy of heavily used assay strengthens market potential for flagship in-clinic diagnostic platform ANN ARBOR, MI / ACCESSWIRE / May 29, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of its improved canine cortisol assay for...Read more
The drug candidate demonstrates antipsychotic activity and has a mechanism of action distinct from FDA-approved therapies for schizophrenia and other mental conditions that present psychotic symptoms Jaguar to receive percent of milestone payments and increasing royalties upon commercialization into the U.S. schizophrenia market, which is estimated to reach $8.06 billion by 2030 Jaguar to present May 30 at Lytham Partners Spring 2024...Read more
SAN FRANCISCO, CA / ACCESSWIRE / May 28, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the results of a third-party, investigator-initiated study of crofelemer, Napo's novel plant-based prescription drug, show that twice daily oral administration of crofelemer led to a statistically meaningful reduction of abdominal pain and discomfort and improved stool consistency...Read more
Data Published in BMC Veterinary Research shows that OKV-119 exenatide implant reduced feline weight Felines share many pathophysiologic obesity phenotypes with humans, further supporting clinical evaluations of miniature, subdermal GLP-1 implants for obesity reduction Development partner, Okava Pharmaceuticals, is studying OKV-119 for the treatment of pre-diabetes, diabetes, and obesity in companion felines ALAMEDA, Calif. / May 28,...Read more
Food and Drug Administration confirms Bovaer meets safety and efficacy requirements Elanco expects product launch and added carbon credit value to producers beginning in the third quarter Elanco announces agreement with dsm-firmenich to expand distribution of Bovaer across North America, adding both the Canada and Mexico markets GREENFIELD, Ind., May 28, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today...Read more
Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Top line results imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea 18 million people in U.S. are living with a cancer diagnosis and more than 2 million people in U.S. are expected to be diagnosed...Read more
ANN ARBOR, MI / ACCESSWIRE / May 21, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024. Company...Read more
OTA capability enhances introduction of new assays from rapidly expanding menu ANN ARBOR, MI / ACCESSWIRE / May 15, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of Over-the-Air ("OTA") software and firmware update capabilities for its TRUFORMA point-of-care...Read more
WESTBROOK, Maine / May 14, 2024 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon, Executive Vice President and Chief Financial Officer, and Michael Lane, Executive Vice President, General Manager, Reference Laboratories and Information Technology, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 29, 2024...Read more
The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased approximately 4% versus net Q4 2023 revenue of $2.3 million Top line results expected to be imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar planning to begin...Read more
PORTLAND, Maine, May 14, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2024. Management’s Discussion “Our preliminary,...Read more
Performance Sets New Record for First Quarter Revenue ANN ARBOR, MI / ACCESSWIRE / May 9, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the first quarter ended March 31, 2024. 2024 First Quarter Financial Highlights Revenue for the first...Read more
Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBS SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family companies Napo Pharmaceuticals ("Napo") and Napo Therapeutics have submitted a Clinical Trial Application (CTA) to the Italian and German health...Read more
First veterinary commercial sale of the SRT-100 outside the U.S. BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of an SRT-100 system to Chavat Da’at, the Veterinary Specialist Referral Center Knowledge...Read more
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE